Nitric Oxide Stimulates ^{18}F-FDG Uptake in Human Endothelial Cells Through Increased Hexokinase Activity and GLUT1 Expression

Jin-Young Paik, MS; Kyung-Han Lee, MD; Bong-Ho Ko, BS; Yearn Seong Choe, PhD; Yong Choi, PhD; and Byung-Tae Kim, MD

Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

The endothelium constitutes a functionally active organ critically involved in angiogenesis. Nitric oxide (NO) is an important regulator of vascular homeostasis and angiogenesis and stimulates glucose metabolism in certain cells. We thus investigated the effect of exogenous NO on ^{18}F-FDG transport in human endothelial cells. **Methods:** Human umbilical vein endothelial cells (HUVECs) were treated with the NO donors sodium nitroprusside (SNP) or diethylenetriamine (DETA), in concentrations of 1 μmol/L–1 mmol/L for up to 24 h. ^{18}F-FDG uptake levels corrected for protein content were determined by cellular radioactivity measured after 30-min incubation. Cells were evaluated for total hexokinase activity and plasma membrane glucose transporter 1 (GLUT1) levels, and involvement of potential signaling pathways was investigated by cotreatment with respective protein kinase inhibitors. **Results:** Both SNP and DETA stimulated HUVEC ^{18}F-FDG uptake, which began at 16 h and peaked at 24 h. The increase in ^{18}F-FDG uptake was dose dependent, reaching 464.0% ± 49.8% and 254.5% ± 10.8% of control levels at 24 h with 1 mmol/L SNP and DETA, respectively. Exposure of HUVECs to 1 mmol/L SNP resulted in a 3.5 ± 0.3-fold elevation in hexokinase activity ($P < 0.01$) and a significant increase in GLUT1 levels. SNP-stimulated ^{18}F-FDG uptake was abolished by cotreatment with cycloheximide, the tyrosine kinase inhibitor genistein, the phosphatidylinositol-3 kinase (PI3K) inhibitor wortmannin, or the protein kinase C inhibitor staurosporine. **Conclusion:** NO stimulates ^{18}F-FDG uptake in HUVECs through an increase in GLUT1 expression and hexokinase activity, which appears to involve both protein kinase C and PI3K pathways.

Key Words: human endothelial cells; hexokinase activity; glucose transporter; ^{18}F-FDG uptake; nitrous oxide

J Nucl Med 2005; 46:365–370

The vascular endothelium is an active, dynamic tissue that controls many important functions, including nutrient exchange, regulation of vascular tone and perfusion, and inflammatory responses (*1*). Endothelial cells are also responsible for promoting angiogenesis in tumor and ischemic lesions (*2,3*). To successfully induce angiogenesis, it is crucial for endothelial cells to metabolically adapt to adverse environments. This is dependent on a sufficient supply of energy, which, in endothelial cells, is predominantly generated by active metabolism of glucose (*4,5*). Therefore, elucidation of mechanisms governing the regulation of glucose transport in endothelial cells is necessary to better understand the process of angiogenesis. In addition, such studies are also important because endothelial glucose transport rates may contribute to the overall uptake of ^{18}F-FDG in tumor or vascular lesions on PET images (*6*).

Nitric oxide (NO) is an important signaling molecule with critical roles in angiogenesis (*7,8*). NO has been shown to stimulate glucose transport in a variety of nonendothelial cells (*9–12*). However, the role of NO in regulating endothelial glucose metabolism has not yet been evaluated. Thus, the purpose of this study was to elucidate the effect of NO on human endothelial cell glucose transport as measured by ^{18}F-FDG uptake and to further investigate the molecular mechanisms involved in such an effect.

MATERIALS AND METHODS

Cell Culture

Human umbilical vein endothelial cells (HUVEC; American Type Culture Collection) were maintained in endothelial cell basal medium (EBM; Clonetics, Cambrex Corp.) supplemented with epidermal growth factors, 12% fetal bovine serum, 2 g/L glucose, and 100 U/mL penicillin-streptomycin in a humidified atmosphere of 5% CO_2 at 37°C. Culture media were changed every 3 d, and only cells from passage 4–5 were used for experiments. To each well of 12-well culture plates, 1×10^5 HUVECs were seeded with 1.5 mL of culture media, which reached 80% confluence 48 h later on the day of experiments.

Exposure to Nitric Oxide Donors

HUVECs were exposed to sodium nitroprusside (SNP; Sigma Chemical Co.) or diethylenetriamine (DETA; Sigma) in concentrations of 1 μmol/L to 1 mmol/L by their addition to the culture medium. Cells were then incubated in a humidified atmosphere of 5% CO_2 at 37°C for 24 h. The concentration of NO released from the NO donors was measured by incubating 100 μL of culture

media with an equal volume of Griess reagent containing 1% sulfanilamide, 0.1% *N*-(1-naphthyl)ethylenediamine dihydrochloride, and 2.5% phosphoric acid for 10 min. Absorbance at 540 nm was measured using a spectrophotometer, and results were expressed as concentration relative to unstimulated cells.

Potential cytotoxic effects of SNP in our experiments were evaluated by inspection of cell morphology, protein assays, and trypan blue assays. Trypan blue assays were performed by incubating SNP (0, 0.5, 1, or 5 mmol/L) treated cells with 0.4% trypan blue for 10 min, followed by counting the percentage of positive staining cells (6 samples per group).

Cellular ^{18}F-FDG Uptake Measurements

Uptake measurements were performed in HUVECs treated with or without various concentrations of SNP or DETA by adding 370 kBq (10 μCi) of ^{18}F-FDG to the culture medium of the cells and incubation in a humidified atmosphere of 5% CO_2 at 37°C. Time course experiments showed that ^{18}F-FDG uptake in HUVECs reached a relative plateau after 30 min incubation (data not shown). Hence, the remaining ^{18}F-FDG uptake experiments were performed with 30-min incubation, when the adherent cells were washed twice with phosphate-buffered saline (PBS), then lysed in 1 mL distilled water before measurement of radioactive counts on a high-energy γ-counter (Wallac). ^{18}F-FDG uptake levels of each sample were corrected for protein content as determined by the Bradford method and expressed as percentage of uptake relative to that of control cells.

Measurement of Total Hexokinase Activity

Total cellular hexokinase activity was measured using the method of Vinuela et al. as modified by Waki et al. (*13*). Briefly, cells were homogenized in a buffer containing 50 mmol/L triethanolamine and 5 mmol/L $MgCl_2$ (pH 7.6), and supernatants containing free and mitochondria-bound hexokinase were obtained by centrifugation at 1,000*g* at 4°C for 5 min. A buffer comprised of the homogenization buffer containing 0.5 mmol/L glucose, 5 mmol/L adenosine triphosphate, 0.25 mmol/L reduced nicotineamide adenine dinucleotide phosphate, and 6 units glucose-6-phosphate dehydrogenase was preincubated at 20°C for 15 min. Samples were then added, and the reaction mixture was measured for absorbance. Hexokinase activity was determined from a standard curve, with 1 unit defined as the enzyme activity that phosphorylates 1 μmol/L of glucose per minute at 20°C. Aliquots were removed to measure the protein content, and the enzyme activity was expressed as mU/mg protein.

Western Blot Analysis for GLUT1 Expression

Two 150-mm plates of 80% confluent HUVECs that were either untreated or treated with 1 mmol/L SNP were used to obtain membrane proteins for Western blot. After culture media were aspirated, the attached cells were washed twice with PBS, then solubilized with 500 μL of lysis buffer containing 0.0856 g/mL sucrose, 10 mmol/L/mL *N*-(2-hydroxyethyl)piperazine-*N'*-(2-ethanesulfonic acid) (HEPES), 25 μmol/L/mL ethylenediaminetetraacetic acid, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 1 mmol/L phenylmethylsulfonylfluoride and centrifuged at 1,000*g* for 20 min. The supernatants from the 2 plates were combined and mixed with 1.5 mL of lysis buffer containing 0.0856 g/mL sucrose, 10 mmol/L/mL HEPES, and 10 mmol/L/mL $MgCl_2$, incubated at 4°C for 1 h, and centrifuged at 45,000 rpm for 60 min, and the pellet was dissolved with a minimum volume of PBS. After measurement of protein content using Bradford assays, 25 μg of membrane protein, which amounts to protein obtained from approximately 1×10^7 HUVECs, were loaded on each lane. The proteins were separated on a 10% polyacrylamide gel, electroblotted to a hydrobond enhanced chemiluminescence nitrocellulose membrane (Amersham Biosciences), and reacted with a polyclonal antibody against human glucose transporter 1 (GLUT1; 1:1,000 dilution; Calbiochem). GLUT1 protein was visualized using a horseradish peroxidase-conjugated secondary antirabbit IgG antibody (1:1,000 dilution; Caltag) and a high-performance chemiluminescence film.

SNU-C5 human colon cancer cells that are known to express very high levels of GLUT1 were used as positive controls. As a negative control, proteins from SNP-treated cells were loaded and underwent procedures as described but without the primary antibody.

Effect of Protein Synthesis Inhibitors and Protein Kinase Inhibitors

To elucidate the cellular signaling pathways involved in the stimulatory effect of NO, we measured ^{18}F-FDG uptake in HUVECs treated with 1 mmol/L SNP for 24 h in the presence or absence of inhibitors of candidate protein kinase pathways. These included 4 μmol/L staurosporine, a protein kinase C (PKC) inhibitor; 200 nmol/L wortmannin, a specific phosphatidylinositol 3-kinase (PI3K) inhibitor, 500 μmol/L genistein, a tyrosine kinase inhibitor; and 100 ng/mL cycloheximide, a protein synthesis inhibitor. The inhibitors were added to cells 1 h before treatment with SNP.

Statistical Analysis

All experiments were repeated at least 3 separate times, and the mean ± SD of triplicate samples from a single representative experiment was presented. The range of results obtained from repeated experiments was also presented. Student *t* test was used to evaluate the statistical significance between groups, and *P* values <.05 were considered significant.

RESULTS

NO Concentration in Media of SNP-Treated HUVECs

Treatment of HUVECs with 1 mmol/L SNP for 24 h led to a significant increase in NO levels released in culture media to 40.7 ± 0.8-fold over that for controls (Fig. 1). The experiment was repeated 2 more times, which showed 32.8 ± 1.7- and 43.3 ± 1.7-fold increases in NO levels (interassay mean, 38.9 ± 5.5-fold increase). The increase in NO by SNP was not affected by the presence of the inhibitors genistein, staurosporine, cycloheximide, or wortmannin, which respectively showed 40.6 ± 0.67-, 36.3 ± 1.8-, 44.8 ± 2.2-, and 46.5 ± 1.6-fold higher NO levels compared with controls (Fig. 1). The interassay averages of SNP-induced NO increases in the presence of the inhibitors were 38.9 ± 6.4-, 40.8 ± 5.7-, 43.0 ± 5.0-, and 32.7 ± 5.1-fold, respectively.

Effect of NO Treatment on HUVEC ^{18}F-FDG Uptake

There was no change in cell morphology or protein content in HUVECs treated with 0.5 or 1 mmol/L SNP for 24 h compared with controls. Trypan blue assays confirmed viability after treatment with 0.5 mmol/L and 1 mmol/L SNP (94.6 ± 1.1 and 94.3% ± 2.3%, respectively) to be

FIGURE 1. Nitric oxide generation levels by SNP. Concentrations were measured in culture media after incubation with 1 mmol/L SNP for 24 h. Data are mean ± SD of a representative experiment with triplicate samples expressed as relative increase compared with controls. SD of control group (first bar on left) is too small to discern. Geni = genistein; Stauro = staurosporine; Cyclo = cycloheximide; Wort = wortmannin; *$P < 0.05$, **$P < 0.01$, ***$P < 0.005$.

comparable with that of untreated controls (94.5% ± 2.0%). In contrast, however, 24-h exposure to 5 mmol/L SNP significantly decreased HUVEC viability to 55.8% ± 2.0% ($P < 0.0001$).

Exposure of HUVECs to either SNP or DETA resulted in a significant enhancement in ^{18}F-FDG uptake in a dose-dependent manner. Treatment with 0.5 and 1 mmol/L SNP for 24 h increased ^{18}F-FDG uptake to 206.3% ± 2.7% and 464.0% ± 49.8%, respectively, of control levels (both $P < 0.001$; Fig. 2A), and the same concentrations of DETA

increased ^{18}F-FDG uptake to 218.9% ± 35.9% ($P < 0.05$) and 309.7% ± 16.1%, respectively ($P < 0.005$; Fig. 2C). The range of ^{18}F-FDG increase stimulated by 24 h of 1 mmol/L SNP observed in 7 separate experiments was between 368.5% ± 26.5% ($P < 0.001$) and 599.3% ± 63.0% ($P < 0.05$) of control levels (interassay mean, 499.3% ± 89.9%). Time course studies using 1 mmol/L SNP or DETA revealed an increase in ^{18}F-FDG uptake at 16 h of exposure (176.5% ± 18.3% and 166.8% ± 8.7%, respectively; both $P < 0.05$; Fig. 2B), with a maximum uptake at 24 h (599.5% ± 63.1%; $P < 0.01$; and 223.9% ± 7.7%; $P < 0.005$; Fig. 2D).

Hexokinase Activity and GLUT1 Expression Levels

Because ^{18}F-FDG is both transported and phosphorylated within the cell, we investigated hexokinase activity and GLUT1 expression levels of HUVECs. After exposure to 1 mmol/L SNP for 24 h, total cellular hexokinase activity was significantly increased to levels 3.5 ± 0.3-fold of those for controls ($P < 0.01$; Fig. 3). In 2 more repeated experiments, hexokinase activity was increased to 2.3 ± 0.2-fold ($P < 0.05$) and 2.5 ± 0.4-fold ($P < 0.001$) of control levels.

Western blot analysis of plasma membrane GLUT1 protein also revealed a significant increase in expression levels in HUVECs treated with 1 mmol/L SNP for 24 h compared with unstimulated controls (Fig. 4). Absence of visible bands in the negative control lane indicates specificity of the Western blot results.

Effect of Inhibitors on NO-Stimulated ^{18}F-FDG Uptake

Cycloheximide completely abolished SNP-stimulated ^{18}F-FDG uptake, resulting in uptake levels of 65.1% ± 2.6% of unstimulated control cells ($P < 0.001$; Fig. 5). In the presence of genistein, ^{18}F-FDG uptake decreased to


FIGURE 2. Relative ^{18}F-FDG uptake levels in HUVECs. Dose dependence of ^{18}F-FDG uptake levels after 24-h incubation with various concentrations of SNP (A) and DETA (C). Time course of increase in ^{18}F-FDG uptake levels in cells treated with 1 mmol/L of SNP (B) and DETA (D). Data are mean ± SD of percentage uptake relative to controls from single experiment representative of 3 (SNP) or 2 (DETA) separate experiments. *$P < 0.01$, **$P < 0.005$, ***$P < 0.001$.

FIGURE 3. Total hexokinase activity. Black bar indicates HUVECs incubated with 1 mmol/L SNP for 24 h. Results are expressed as mean ± SD of mU/mg protein of triplicate samples obtained from single experiment representative of 3 separate experiments.

133.6% ± 9.0% of control levels compared with 427.0% ± 8.8% in its absence ($P < 0.001$; Fig. 5). Wortmannin significantly attenuated the SNP effect and resulted in ^{18}F-FDG uptake that was only 109.0% ± 4.5% of control levels ($P < 0.001$ compared with SNP-treated cells without wortmannin; Fig. 6). Staurosporine completely blocked the SNP effect, resulting in ^{18}F-FDG uptake levels even lower than those of unstimulated control cells (72.2% ± 2.8%; $P < 0.001$ compared with SNP-treated cells without staurosporine; Fig. 6).

In 3 separate experiments, the interassay means of SNP-induced ^{18}F-FDG uptake in the presence of genistein, cycloheximide, wortmannin, and staurosporin were 191.5% ± 54.2%, 59.4% ± 19.2%, 116.5% ± 47.0%, and 35.1% ± 6.6% of control levels, respectively.

DISCUSSION

Our study showed that exogenous NO significantly stimulates ^{18}F-FDG uptake in HUVECs and is accompanied by an increase in cellular hexokinase activity and GLUT1 expression levels.

NO plays an important role in normal and pathologic vascular biology and is a critical mediator of angiogenesis (7). Angiogenic factors induce endothelial release of NO, which in turn mediates a multiplicity of angiogenic processes, such as endothelial cell survival, proliferation, and


FIGURE 4. Representative Western blot for plasma membrane GLUT1. SNU-C5, human colon cancer cells; SNP, HUVECs treated with 1 mmol/L SNP; control, untreated HUVECs; negative, HUVECs treated with 1 mmol/L SNP but without application of primary antibody.


FIGURE 5. Effect of cycloheximide and genistein on SNP-stimulated ^{18}F-FDG uptake. Inhibitors were added 1 h before 24-h stimulation with 1 mmol/L SNP. Results are expressed as percentage of uptake relative to mean of controls. Data are mean ± SD of triplicate samples from single experiment representative of 3 separate experiments. ***$P < 0.001$.

migration, whereas derangements in NO synthesis impair angiogenesis (14,15).

NO donors are also known to have dose-dependent cytotoxic effects on various cell types. Ioannidis et al. (16) reported damage of rat sinusoidal endothelial cells treated with 5 mmol/L SNP, and Gooch et al. (17) observed cytotoxic effects in bovine aortic endothelial cells treated with 1 mmol/L SNP after 24-h incubation but not in HUVECs treated with 0.7 mmol/L SNP. Under our experiment conditions, however, we confirmed that treatment for 24 h with SNP concentrations of up to 1 mmol/L did not cause sig-


FIGURE 6. Effect of wortmannin and staurosporine on SNP-stimulated ^{18}F-FDG uptake. Inhibitors were added 1 h before 24-h stimulation with 1 mmol/L SNP. Results are expressed as percentage of uptake relative to mean of controls. Data are mean ± SD of triplicate samples from single experiment representative of 3 separate experiments. ***$P < 0.001$.

nificant cytotoxic effects, although cytotoxicity was observed with 5 mmol/L SNP.

This study revealed that, in addition to proangiogenic effects, NO also has a role in augmenting endothelial cell glucose transport. Endothelial cells are the principal effector cells of angiogenesis, and their survival and function are dependent on the availability and utilization of energy substrates. Endothelial cells are now recognized to rapidly transport and actively metabolize glucose (18). Endothelial glucose metabolism is upregulated in response to such stimuli as exposure to hypoxia, glucose deprivation, or treatment with growth factors (6,19–21). These stimuli have generally been shown to increase glucose transport activity after 12–24 h of treatment, which is similar to the SNP exposure time required for maximum ^{18}F-FDG uptake in our study (19,21).

To our knowledge, the effect of NO on endothelial cell glucose metabolism has not been previously reported. On the other hand, NO has previously been observed to augment glucose metabolism in such cells as skeletal and cardiac myocytes, vascular smooth muscle cells, and adipocytes (9–12). The key steps that control cellular utilization of glucose are its translocation across plasma membrane through its transporters and subsequent phosphorylation by hexokinase. For insulin-responsive cells, such as adipocytes or myocytes, NO is known to enhance glucose transport via an increase in GLUT4 levels (11,12).

For endothelial cells, GLUT1 is the predominant and most abundant glucose transporter isoform (18). Endothelial GLUT1 expression is upregulated in response to hypoxia or glucose deprivation and by treatment with vascular endothelial growth factor (VEGF) (19–22). Our results show that NO is yet another stimulant that upregulates GLUT1 levels in endothelial cells. In addition to GLUT1 expression, we also found a significant increase in hexokinase activity for HUVECs treated with SNP. Taken together, our results indicate that both membrane expression of GLUT1 and hexokinase activity contribute to the observed augmented ^{18}F-FDG uptake induced by NO.

The molecular mechanisms that govern cellular glucose metabolism are diverse, and multiple signaling cascades might be involved in its regulation for different cells. In our study, the protein synthesis inhibitor cycloheximide completely abolished the increase in ^{18}F-FDG uptake, indicating that the SNP effect may require new protein synthesis. In addition to inhibition of protein synthesis, however, other effects of cycloheximide have been described for both increased and decreased glucose transport, which may be related to interference of cycloheximide with intrinsic activity or with GLUT translocation and retranslocation (23).

We also found that the SNP effect was significantly attenuated in the presence of genistein. Genistein is a potent tyrosine kinase inhibitor and has been shown to limit angiogenesis and inhibit insulin-stimulated cardiomyocyte glucose transport (24,25).

NO activates soluble guanylyl cyclase, which results in an increased intracellular synthesis of cyclic guanosine 3′,5′-cyclic monophosphate (cGMP). cGMP activates cGMP-dependent protein kinases that mediate localized and global signaling related to major NO effects (26). PI3K-Akt is activated by many angiogenesis promoting growth factors, and serves as a key mediator of such angiogenic processes as endothelial cell survival, proliferation, and migration (27). The PI3K-Akt pathway has been shown to mediate NO-induced endothelial cell migration and angiogenesis (8). PI3K-Akt also has a well-known central role in increasing glucose metabolism in insulin-responsive cells (28). In our study, the specific PI3K inhibitor wortmannin showed potent blocking of the SNP effect, indicating that it is partly mediated through activation of the PI3K-Akt pathway.

The PKC inhibitor staurosporine was a potent suppresser of the SNP effect, and cotreatment of HUVECs resulted in ^{18}F-FDG uptake levels that were even lower than those in unstimulated controls. The PKC pathway has been reported to mediate VEGF-induced activation of endothelial Akt and stimulate angiogenesis (29). It has also been shown that PKC is essential for VEGF- and insulin-like growth factor-1-stimulated endothelial glucose transport (21,30). Notably, both PI3K and PKC were required for the stimulatory effect of insulin-like growth factor-1, which is similar to what we observed for the NO effect.

Taken together, the results of our inhibition experiments suggest that the actions of NO in stimulating HUVEC glucose transport involve interactions between multiple protein kinase pathways that require both PI3K and PKC. Because inhibition of PI3K and that of PKC each resulted in potent blocking of the SNP effect, activation of these pathways appears to occur in a sequential manner rather than in parallel.

CONCLUSION

NO enhances ^{18}F-FDG uptake in human HUVECs together with an increase in membrane GLUT1 expression and hexokinase activity via pathways that involve both PI3K and PKC. These findings suggest an important role for NO in modulating glucose transport of endothelial cells.

REFERENCES

1. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. *Am J Med.* 2003;115(suppl 8A):99S–106S.

2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000;407:249–257.

3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med.* 2000;73: 389–395.

4. Mertens S, Noll T, Spahr R, Krutzfeldt A, Piper HM. Energetic response of coronary endothelial cells to hypoxia. *Am J Physiol.* 1990;258:H689–H694.

5. Culic O, Decking UKM, Schrader J. Metabolic adaptation of endothelial cells to substrate deprivation. *Am J Physiol Cell Physiol.* 1999;276:C1061–C1068.

6. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T. Characterization of ^{18}F-FDG uptake in human endothelial cells in vitro. *J Nucl Med.* 2004;45:455–460.

7. Schmidt HH, Walter U. NO at work. *Cell.* 1994;78:919–925.

8. Kawasaki K, Smith RS, Hsieh C-M, Sun J, Chao J, Liao JK. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. *Mol Cell Biol.* 2003;5726–5737.

9. Higaki Y, Hirshman MF, Fujii N, Goodyear LJ. Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. *Diabetes.* 2001;50:241–247.

10. Jensen J, Sharikabad MN, Ostbye KM, Melien O, Brors O. Evidence that nitroprusside stimulates glucose uptake in isolated rat cardiomyocytes via mitogen-activated protein kinase. *Arch Physiol Biochem.* 2003;111:239–245.

11. Bergandi L, Silvagno F, Russo I, et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2003;23:2215–2221.

12. Tanaka T, Nakatani K, Morioka K, et al. Nitric oxide stimulates glucose transport through insulin-independent GLUT4 translocation in 3T3–L1 adipocytes. *Eur J Endocrinol.* 2003;149:61–67.

13. Waki A, Kato H, Yano R, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. *Nucl Med Biol.* 1998;25:593–597.

14. van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/ vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. *Circulation.* 1997;97:1030–1037.

15. Cooke JP. NO and angiogenesis. *Atheroscler Suppl.* 2003;4:53–60.

16. Ioannidis I, Batz M, Paul T, Korth HG, Sustmann R, De Groot H. Enhanced release of nitric oxide causes increased cytotoxicity of S-nitroso-N-acetyl-DL-penicillamine and sodium nitroprusside under hypoxic conditions. *Biochem J.* 1996;318:789–795.

17. Gooch KJ, Dangler CA, Frangos JA. Exogenous, basal, and flow-induced nitric oxide production and endothelial cell proliferation. *J Cell Physiol.* 1997;171: 252–258.

18. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. *Physiol Rev.* 2003;83:183–252.

19. Loike JD, Cao L, Brett J, Ogawa S, Silverstein SC, Stern D. Hypoxia induces glucose transporter expression in endothelial cells. *Am J Physiol.* 1992;263: C326–C333.

20. Gaposchkin CG, Garcia-Diaz JF. Modulation of cultured brain, adrenal, and aortic endothelial cell glucose transport. *Biochim Biophys Acta.* 1996;1285:255–266.

21. Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. *Invest Ophthalmol Vis Sci.* 2000;41:1876–1884.

22. Takagi H, King GL, Aiello LP. Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. *Diabetes.* 1998;47:1480–1488.

23. Binder C, Binder L, Kroemker M, Schulz M, Hiddemann W. Influence of cycloheximide-mediated downregulation of glucose transport on TNF alpha-induced apoptosis. *Exp Cell Res.* 1997;236:223–230.

24. Boros LG, Bassilian S, Lim S, Lee WN. Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. *Pancreas.* 2001;22:1–7.

25. Colston VL, Wheeler TJ. Stimulation of cardiac glucose transport by inhibitors of oxidative phosphorylation. *Life Sci.* 2001;69:2383–2398.

26. Schlossmann J, Feil R, Hofmann F. Signaling through NO and cGMP-dependent protein kinases. *Ann Med.* 2003;35:21–27.

27. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. *Circ Res.* 2002;90:1243–1250.

28. Summers SA, Birnbaum MJ. A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake. *Biochem Soc Trans.* 1997;25:981–988.

29. Gliki G, Wheeler-Jones C, Zachary I. Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase mediates PKC delta phosphorylation: role of PKC in angiogenesis. *Cell Biol Int.* 2002;26:751–759.

30. DeBosch BJ, Baur E, Deo BK, Hiraoka M, Kumagai AK. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. *J Neurochem.* 2001;77:1157–1167.